 |
인쇄하기
취소
|
Korea in the running to be global leader for biosimilars by 2017
The Ministry of Food and Drug Safety (MFDS) unveiled a set of plans on Aug. 30 to nurture seven globally competitive biopharmaceutical companies by 2017.
The plans are intended to develop Korea into the seventh-largest power in the bioindustry.
Under the arrangement, the MFDS will approve a total of 10 biosimilars and stem cell therapies as well as 20 homegrown vaccines by 2017 by keeping...
The plans are intended to develop Korea into the seventh-largest power in the bioindustry.
Under the arrangement, the MFDS will approve a total of 10 biosimilars and stem cell therapies as well as 20 homegrown vaccines by 2017 by keeping...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.